Last reviewed · How we verify
NCT07365202: OFFPAV
Osteosynthesis of Fibula Fractures With a Locked Thin Plate
trial in Osteosynthesis of Fibula Fractures With a Locked Thin Plate in 40 participants. Not yet recruiting.
15 December 2026
Quick facts
| Lead sponsor | University Hospital, Grenoble |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 15 January 2026 |
| Primary completion | 15 December 2026 |
| Estimated completion | 15 December 2026 |
| Sites | 1 location across France |
Conditions studied
- Osteosynthesis of Fibula Fractures With a Locked Thin Plate — all drugs for Osteosynthesis of Fibula Fractures With a Locked Thin Plate →
Sponsor
University Hospital, Grenoble
Who can join
Adults 18 to 100, any sex, with Osteosynthesis of Fibula Fractures With a Locked Thin Plate. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ankle fractures represent about 10% of all fractures and are common in both elderly patients with comorbidities and younger polytraumatized individuals. Traditional fibular osteosynthesis uses open plating, which carries up to a 20% complication rate, mainly due to skin issues. These complications are more frequent in patients with diabetes, vascular or neurological disease, obesity, or tobacco/alcohol use, as well as in open fractures or fracture-dislocations. Standard plates can also cause long-term discomfort due to their thickness, often requiring removal. Recent meta-analyses show that fibular nailing and thin one-third tubular plates result in fewer complications than anatomical plates, while maintaining similar bone-healing rates (97-100%). New thinner locked plates (2.8 mm) have been developed to reduce skin risks and discomfort; biomechanical studies suggest superior strength. Clinical research is needed to confirm their effectiveness and tolerance.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07365202
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Grenoble trials
Trials by the same sponsor.
- NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
- NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
- NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
- NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
- NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07365202 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
- Last refreshed: 26 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07365202.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing